Aspirin and NSAIDs protect against colorectal cancer

Long-term use of low-dose aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the risk of developing colorectal cancer, new research suggests.

The Danish study included 10,280 patients with colorectal cancer and 102,800 controls. Over use (=2 prescriptions) of low-dose (75-150mg) aspirin was not significantly associated with the risk of developing colorectal cancer (CRC). Over use of non-aspirin NSAIDs, however, was associated with a 6% reduction in colorectal cancer risk.

Taking low-dose aspirin continuously for at least five years was associated with a 27% reduction in colorectal cancer risk. Consistent use of non-aspirin NSAIDs for at least five years (=2 prescriptions annually) was associated with a 36% reduction.